[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ground-glass-opacity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ground-glass-opacity":54},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100581328","cryoablation-vs-thoracoscopic-surgery-for-ggn-100581328",false,"NCT06848881","Cryoablation vs Thoracoscopic Surgery for GGN","Cryoablation Versus Thoracoscopic Surgery for Pulmonary Ground-Glass Nodules: A Prospective, Comparative, Open Label Study","Inclusion Criteria:\n\n1. Patients ≥ 18 years old.\n2. The size of the GGN is 8-20mm (with less than 25% solid component), and the number of nodules requiring treatment in the short term is less than 3.\n3. Pathological confirmation of the GGN as non-small cell lung cancer; or progression of the GGN during at least 3 months of follow-up, including enlargement of the largest diameter, increase in solid component, or the appearance of a significant solid component in a previously pure GGN, with multidisciplinary discussion (including radiology, thoracic surgery, and pulmonology) suggesting malignancy.\n4. No lymph node, pulmonary, or distant metastasis to other organs.\n5. After multidisciplinary evaluation, the patient is considered capable of tolerating both surgical and ablation procedures.\n6. Unsuitable for radiation therapy or refusal of radiation therapy.\n7. Willing to participate in this clinical study and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients in poor general condition, with ECOG physical fitness score \\>2, unable to tolerate surgery or ablation therapy, or with relevant contraindications.\n2. Patients who have previously received other treatments for pulmonary GGNs.\n3. Patients with poor compliance.\n4. Severe heart, lung, kidney, brain, or other vital organ diseases.\n5. Active bacterial or fungal infections.\n6. Simultaneous or metachronous (within the past 5 years) double cancers.\n7. Women during pregnancy or breast-feeding.\n8. History of radiation therapy.\n9. Bleeding tendency, abnormal coagulation functions, or coagulation disorders that cannot be corrected after treatment.\n10. Contraindications to general anesthesia.\n11. Expected survival time \\\u003C 6 months.\n12. The researcher believes that it is not suitable for inclusion.","ALL","18 Years",{"count":19,"type":20},160,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this study is to investigate the efficacy and safety of Cryoablation and Thoracoscopic Surgery in the treatment of pulmonary ground-glass nodules.",[26],"Ground-Glass Opacity","RECRUITING","2026-03-18",{"date":30,"type":31},"2026-03-20","ACTUAL",{"date":33,"type":31},"2025-04-20",{"date":35,"type":20},"2030-04-15",{"name":37,"class":38},"Shanghai Chest Hospital","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100622920","percutaneous-robotic-navigation-microwave-ablation-versus-ct-guided-microwave-ablation-in-the-treatment-of-pulmonary-nodules-with-ground-glass-opacity-100622920","NCT07389889","Percutaneous Robotic Navigation Microwave Ablation Versus CT-guided Microwave Ablation in the Treatment of Pulmonary Nodules With Ground-glass Opacity","Percutaneous Robotic Navigation Microwave Ablation Versus CT-guided Microwave Ablation in the Treatment of Pulmonary Nodules With Ground-glass Opacity: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n1. Aged 18 to 85 years\n2. Nodules measuring 3-30mm with ground-glass opacities constituting ≥75% of the lesion\n3. Preoperative clinical evaluation confirming no hilar or mediastinal lymph node metastasis and no distant metastasis\n4. Patients diagnosed as stage IA primary peripheral lung cancer according to the UICC 8th TNM staging system, and with one of the following conditions:\n\n   (i) cannot undergo surgical resection due to poor cardiopulmonary function or advanced age (ii) refusing or unwilling to undergo surgical resection (iii) with newly developed or residual pulmonary nodules after early-stage primary lung cancer surgery (iv) with unilateral lung disease who cannot undergo unilateral surgical resection (v)with multiple primary lung cancers unsuitable for surgical resection\n5. Preoperative ECOG physical status score is 0\u002F1\n6. ASA score is I-III\n7. Patients voluntarily participate in this study and sign the informed consent form\n\nExclusion Criteria:\n\n1. Smoking cessation duration \\\u003C2 weeks\n2. Lesions adjacent to pulmonary artery-vein main trunks\n3. Lesions near the hilum or adjacent to lobar bronchi\n4. Pregnancy or lactation status\n5. Severe mental disorders\n6. History of other malignancies within 5 years\n7. Unstable angina or myocardial infarction within 6 months with coronary angiography showing severe stenosis of major coronary branches\n8. Cerebral infarction or hemorrhage within 6 months\n9. Continuous systemic corticosteroid therapy within 1 month\n10. Patients or their authorized persons who do not wish to comply with the study protocol\n11. Patients with other investigator-assessed ineligibility for the trial","85 Years",{"count":49,"type":20},116,[23],"1. To compare the precision of robot-guided microwave ablation and CT-guided microwave ablation in the treatment of ground-glass nodules.\n2. To evaluate the safety of robot-assisted microwave ablation and CT-guided microwave ablation in the treatment of ground-glass nodules.\n3. Explore the application potential of robot navigation microwave ablation technology in the treatment of pulmonary nodules.",[53,54],"Pulmonary Nodules","Ground-glass Opacity",[56],"ggo","NOT_YET_RECRUITING","2026-02-03",{"date":60,"type":31},"2026-02-05",{"date":62,"type":20},"2026-02-01",{"date":64,"type":20},"2029-02-01",{"name":66,"class":38},"Fujian Medical University Union Hospital",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":39},"100523934","phase-3-wedge-resection-for-ground-glass-opacity-featured-lung-cancer-ectop-1020-100523934","NCT06102161","Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)","Wedge Resection for Ground-glass Opacity-featured Lung Cancer With Size Less Than 2cm and Consolidation-to-tumor Ratio Between 0.25 to 0.5: a Single-arm, Multi-center, Prospective, Confirmatory Phase III Trial","Inclusion Criteria:\n\n1. Patients who sign the informed consent form and are willing to complete the study according to the plan;\n2. Aged from 18 to 80 years old;\n3. ECOG equals 0 or 1;\n4. Not receiving lung cancer surgery before;\n5. Intraoperative or postoperative pathologic diagnosis of lung adenocarcinoma;\n6. Single lung nodules with ground-glass dominant or pure ground-glass on CT, or multiple lung nodules with the major lesion being the aforementioned nodules;\n7. The nodule has a consolidation-to-tumor ratio (CTR) between 0.25 and 0.5 (including 0.25 and 0.5), and the nodule size is less than or equal to 2 cm;\n8. peripheral type of nodes, namely, nodes in the outer 1\u002F3 of the lung field.\n9. cT1N0M0 tumors;\n10. Complete tumor resection by wedge resection as assessed by the surgeon;\n11. Not receiving chemotherapy or radiotherapy before.\n\nExclusion Criteria:\n\n1. Postoperative pathologic diagnosis of adenocarcinoma in situ or minimally invasive adenocarcinoma.\n2. CTR is not between 0.25-0.5 or nodule size greater than 2 cm;\n3. Cannot be completely resected by wedge resection;\n4. Invasive lung adenocarcinoma or lung malignancy other than lung adenocarcinoma diagnosed cytologically or pathologically;\n5. Receiving lung cancer surgery before;\n6. Receiving radiotherapy or chemotherapy.","80 Years",{"count":76,"type":20},286,[78],"PHASE3","This is a clinical trial from the Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1020. The goal of this clinical trial is to confirm the therapeutic effect of Wedge resection for ground-glass opacity-featured lung cancer with a size less than 2cm and a consolidation-to-tumor ratio between 0.25 to 0.5.",[81,82,54],"Lung Cancer","Wedge Resection","2023-10-25",{"date":85,"type":31},"2023-10-26",{"date":87,"type":20},"2023-11",{"date":89,"type":20},"2030-11",{"name":91,"class":38},"Fudan University"]